CN105153150B - One class pyridine salt JAK inhibitor, preparation method and its usage - Google Patents
One class pyridine salt JAK inhibitor, preparation method and its usage Download PDFInfo
- Publication number
- CN105153150B CN105153150B CN201510501161.3A CN201510501161A CN105153150B CN 105153150 B CN105153150 B CN 105153150B CN 201510501161 A CN201510501161 A CN 201510501161A CN 105153150 B CN105153150 B CN 105153150B
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- formula
- preparation
- lithium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
The present invention relates to a class containing the JAK inhibitor of pyridiniujm structure, its preparation method and the application in the disease medicaments such as preparation treatment immunity, inflammatory, autoimmunity or allergic disease, or transplant rejection.Wherein, R is selected from C1‑C3Alkyl.
Description
Technical field
The present invention relates to immunity, inflammatory, autoimmunity or allergic disease, or the medicine of the disease such as transplant rejection
Field.In particular it relates to above-mentioned disease have a medicative class containing pyridiniujm structure JAK inhibitor,
Its preparation method, and the purposes in pharmacy.
Background technology
The phosphorylation of kinase catalytic protein, lipid, sugar, nucleoside and other cell metabolites at eukaryotic cell physiology
All aspects play a crucial role.Especially, protein kinase and lipid kinase participate in signal conductive process, and this process control is to carefully
The outer instrumentality of born of the same parents or irritate the cell that thing (such as somatomedin, cytokine or chemotactic factor) responds activation, grow, break up and
Survival.Generally, protein kinase is divided into two classes, the protein kinase of preferential phosphorylation tyrosine residue and preferential phosphorylation serine
And/or the protein kinase of threonine residues.Tyrosine kinase includes transmembrane growth factor receptor such as EGF-R ELISA
And cytosolic non-receptor kinases such as Janus kinases (JAK) (EGFR).High protein kinase activity relates to numerous disease inadequately, bag
Include cancer, metabolic disease, autoimmunity or inflammatory disease.This effect can be directly or indirectly because the sudden change of enzyme, excessively
Express or inappropriate activate produce control mechanism fault and cause.In all these examples, it is desirable to kinase whose selectivity presses down
The useful effect of fixture.
Oneself is nonreceptor tyrosine kinase through becoming a class kinases of current drug development focus] anus kinases (JAK)
Family.In mammal, this family has four members, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).Each egg
White matter all has kinases territory and catalytically inactive pseudokinase territory.JAK protein (carries 4.1 albumen by its amino terminal FERM
(Band-4.1), ezrin (ezrin), radixin (radixin), moesin (moesin) territory are attached to cell factor receptor
On body.After cytokine is combined with its receptor, activates JAKs and make receptor phosphorylation, thus producing for signal transduction molecule
The docking site (docking sites) of (the especially member of signal transducer and transcription activator (Stat) family)
(Yamaoka etc., 2004, The Janus kinases (jaks) .Genome Biology, 5 (12), p253).Mammal
In, JAK1, JAK2 and TYK2 generally express.On the contrary, the expression of JAK3 mainly in hematopoietic cell and by cell development with swash
The altitude mixture control (Musso etc., 1995,181 (4), p1425-1431) lived.JAK mono-deficient cells system and gene target mice
Basic in cytokine signaling conducts of oneself disclosed JAKs of research, unduplicated function.JAK1 knock-out mice shows
Perinatal stage lethal phenotype, may with stop its suckling effects on neural system relevant (Rodig etc., 1998, Ce1l, 93 (3): 373-
383).Due to Dyserythropoiesis, the deletion of JAK2 gene causes producing embryonic lethal when embryo the 12.5th day
(Neubauer etc., 1998, Ce1l, 93 (3), 397-409).Enjoyably, JAK3 defect is suffering from autosomal recessive weight first
In the people of degree combined immunodeficiency (SCID) identified (Macchi etc., 1995, Nature, 377 (6544): 65-68).JAK3 strikes
Except mice displays that SCID but do not show non-immunity defect, show that JAK3 inhibitor will have in vivo as immunosuppressant
Limited effect and therefore become for the promising medicine of immunosuppressant (Papageorgiou and Wikman, 2004, Trends
in Pharmacological Sciences,25(11),558-562).Acute megakaryoblastic leukemia (AMKL) patient
In oneself it be observed that the activated mutant (Walters etc., 2006, Cancer Cell, 10 (1), 65-75) of JAK3.These of JAK3
Ba/F3 cells switch can be factor independent growth and induce megakaryoblastic leukemia in mouse model by mutant form
Feature.
The disease relevant with JAK3 suppression and disease are further described in such as WO01/42246 and WO2008/060301
In.In document oneself report some JAK3 inhibitor can be used for medical domain (O ' Shea etc., 2004, Nat.Rev.Drug
Discov.3(7):555-564).It is reported, effective JAK3 inhibitor (CP-690,550) is at the animal model of organ transplantation
(Changelian etc., 2003, Science, 302 (5646), 875-888) and clinical trial (reference: Pesu etc., 2008,
Immunol.Rev.223,132-142) display effect in.The substituted pyrimidine compound of fluorine is described in WO-as JAK3 inhibitor
In A2010/118986.Heterocyclic radical Pyrazolopyrimidine analogs is described in WO-A2011/048082 as JAK inhibitor.WO-
A2008/129380 relates to treat the sulfamide derivative of abnormal cell growth.WO-A2006/117560 and Journal
Of Molecular Graphics and Modelling (29) 2010,309-320 describe the substituted pyrimidine of pyrazolyl amino and
Its purposes in treatment cancer.EP1054004A1 describes pyrimidine derivatives and the purposes in inflammation thereof.
The invention discloses the class JAK inhibitor containing pyridiniujm structure, these compounds can be used for preparation treatment immunity
Property, inflammatory, autoimmunity or allergic disease, or the medicine of the disease such as transplant rejection.
Summary of the invention
It is an object of the present invention to provide the JAK inhibitor of a kind of excellent activity with formula I.
It is a further object to provide the method that preparation has compounds of formula I.
It is also another object of the present invention to provide containing compounds of formula I in treatment immunity, inflammatory, autoimmunity
Or the application in terms of allergic disease, or the disease such as transplant rejection.
In conjunction with the purpose of the present invention, present invention is specifically described.
The present invention has compounds of formula I and has a following structural formula:
Wherein, R is selected from C1-C3Alkyl.
The compound of preferred formula I has following structure,
Compound of Formula I of the present invention can be synthesized by following route:
Compound II first processes with highly basic, then reacts with compound III, obtains compound IV；Compound IV first uses highly basic
Process, then with 1,2-dichloroethanes reacts, and obtains compound V；There is Intramolecular substitution reaction in compound V, obtains under heating
Compound I；Wherein, described highly basic is selected from n-BuLi, isobutyl group lithium, tert-butyl lithium, phenyl lithium, lithium diisopropylamine, institute
Stating X=Cl, Br, I, R's is defined as described above.
Compound of Formula I of the present invention has JAK inhibitory action, can be used for preparing immunity, inflammation as effective ingredient
Property, autoimmunity or allergic disease, or the disease therapeuticing medicine such as transplant rejection.Compound of Formula I of the present invention
Activity is to be verified by the inhibition test of external JAK.
The compound of Formula I of the present invention is effective in comparatively wide dosage range.The dosage that such as every day takes is about
In the range of 1mg-700mg/ people, it is divided into once or is administered for several times.The actual dosage taking compound of Formula I of the present invention can be by curing
Take root and determine according to relevant situation.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that following embodiment is only for
Illustrate, and be not intended to limit the present invention.Those skilled in the art all should according to the various changes that the teachings of the present invention is made
Within the protection domain required by the application claim.
The synthesis of embodiment 1 compound I-1
The synthesis of step A. compound IV-1
Compound II-1 (1.08g, 10mmol) is dissolved in the THF that 10mL is dried, stirring, be cooled in nitrogen atmosphere-
20 DEG C, then slowly drip the hexane solution (6.25mL, 10mmol) of the n-BuLi of 1.6M with syringe, after dropping,
Reactant mixture continues to stir 1 hour at such a temperature.The most slowly drip III-1 (2.01g, 10mmol) to be dissolved in syringe
The solution that the THF that 3mL is dried makes, after dropping, reactant mixture stirs half an hour at such a temperature, is then warming up to room
Temperature is stirred for overnight.Reactant mixture carefully pours in 200mL frozen water, and stirring, with 50mL × 3CH2Cl2Extraction, merges extraction
Phase, washs with saline, and anhydrous sodium sulfate is dried.Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and residue uses
Silica gel column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=229 ([M+H]+).Step B. compound V-
The synthesis of 1
Compound IV-1 (1.37g, 6mmol) is dissolved in the THF that 10mL is dried, stirring, is cooled to-20 in nitrogen atmosphere
DEG C, the hexane solution (3.75mL, 6mmol) of the n-BuLi of 1.6M is then slowly dripped with syringe, after dropping, reaction
Mixture continues to stir 1 hour at such a temperature.1,2-dichloroethanes (0.99g, 10mmol) is the most slowly dripped molten with syringe
The solution that the THF being dried in 3mL makes, after dropping, reactant mixture stirs half an hour at such a temperature, is then warming up to
Room temperature is stirred for overnight.Reactant mixture carefully pours in 200mL frozen water, and stirring, with 50mL × 3CH2Cl2Extraction, merges extraction
Taking phase, wash with saline, anhydrous sodium sulfate is dried.Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, and residue makes
Purify with silica gel column chromatography, obtain compound V-1, white solid, ESI-MS, m/z=291 ([M+H]+)。
The synthesis of step C. compound I-1
Compound V-1 (0.87g, 3mmol) is dissolved in the toluene that 10mL is dried, heated overnight at reflux in nitrogen atmosphere,
TLC display reaction completes.After reactant mixture is cooled to room temperature, adds 10mL normal hexane, stir 1 hour, collected by suction solid,
Ambient temperature in vacuum is dried, and obtains compound I-1, white solid, ESI-MS, m/z=255 ([M-Cl-]+)。
Embodiment 2-8
With reference to the method for embodiment 1, synthesize compound listed in Table.
Embodiment 9 Compound ira vitro inhibitory action to jak kinase
Using the test as hereafter specified, the ability for compound suppression JAK1, JAK2 and JAK3 carrys out SCREENED COMPOUND.
Use baculovirus expression system, make people JAKl (aa850-1154), JAK2 (aa826-1132), JAK3
And the catalyst structure domain of TYK2 (aa871-1187) is expressed as N end gst fusion protein and it is purchased from Carna (aa795-1124)
Biosciences.Use biotin labeled peptide--poly-(GT)-biotin (CisBio)--as substrate to measure the clean of enzyme
Property.Peptide concentration in reaction is 60nM for JAKl, is 20nM for JAK2, is 140nM for JAK3 and for TYK2 is
50nM.By TR-FRET (time-resolved fluorescence energy transfer (time-resolved fluorescence energy
Transfer)) method detects the degree of phosphorylation.For at 8mM MOPS (pH7.0), 10mM MgC12, 0.05% β-dredge base
Each kinases in the reactant mixture containing enzyme, ATP and peptide in ethanol, 0.45mg/mL BSA measures the IC of compound50.Instead
ATP concentration in Ying is 3 μMs for JAK1, is 0.2 μM for JAK2, for JAK3 is 0.6 μM and is 1.8 μMs for TYK2.
Enzyme process reaction is at room temperature carried out 30 minutes.Then 0.115 μ g/mL anti-valine phosphorylation (phosphoTyr) is contained with 20 μ L
(PT66) the floating detection buffer (50mM that goes out of the SA-XL665 (CisBio) of-cryptate (CisBio) and variable concentrations
HEPES, 0.5M KF, EDTA 0.25M, 0.l% (w/v) BSA, pH7.5) non-stopped reaction to be to keep SA-B ratios constant.Incubate
Educate 3 hours, be then set as reading the upper reading of Victor2V spectrofluorimeter (PerkinElmer) of fluorescence resonance energy transmission
Take.
From upper table result it can be seen that the compound of the present invention has the strongest inhibitory action to JAK, can be as preparation
The medicine of the diseases such as treatment immunity, inflammatory, autoimmunity or allergic disease, or transplant rejection.
Claims (6)
1. there is the compound of general formula I,
Wherein, R is selected from C1-C3Alkyl.
2. compound of Formula I defined in claim 1, is selected from:
3. synthesis claim 1-2 arbitrary defined in belong to the method for compounds of formula I:
Compound II first processes with highly basic, then reacts with compound III, obtains compound IV；Compound IV first processes with highly basic,
Again with 1,2-dichloroethanes reacts, and obtains compound V；There is Intramolecular substitution reaction in compound V, obtains compound under heating
I；Wherein, described highly basic is selected from n-BuLi, isobutyl group lithium, tert-butyl lithium, phenyl lithium, lithium diisopropylamine, described X=
Cl, Br, I, the definition of R is as described in claim 1-2.
4. the defined compound of Formula I purposes in terms of preparing JAK inhibitor medicaments of one of claim 1-2.
5. the purposes described in claim 4, including for preparing treatment immunity, inflammatory, allergic disease, transplant rejection disease
Medicine.
6. the application described in claim 5, wherein immune disease is autoimmune disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510501161.3A CN105153150B (en) | 2015-08-14 | 2015-08-14 | One class pyridine salt JAK inhibitor, preparation method and its usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510501161.3A CN105153150B (en) | 2015-08-14 | 2015-08-14 | One class pyridine salt JAK inhibitor, preparation method and its usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105153150A CN105153150A (en) | 2015-12-16 |
| CN105153150B true CN105153150B (en) | 2016-09-14 |
Family
ID=54794239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510501161.3A Active CN105153150B (en) | 2015-08-14 | 2015-08-14 | One class pyridine salt JAK inhibitor, preparation method and its usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105153150B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044015A (en) * | 1975-09-03 | 1977-08-23 | Pfizer Inc. | Imidazopyridinium compounds as hypoglycemic agents |
| BRPI0810411B8 (en) * | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | sulfonyl amide derivatives for the treatment of abnormal cell growth, their sos, as well as pharmaceutical composition |
-
2015
- 2015-08-14 CN CN201510501161.3A patent/CN105153150B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105153150A (en) | 2015-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105283454B (en) | Quinazoline and azepine quinazoline as RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR access double inhibitor | |
| ES2718550T3 (en) | Bridge urea analogs substituted as sirtuin modulators | |
| EA039357B1 (en) | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer | |
| TW201105674A (en) | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| CN109790158B (en) | Heterocyclic compounds as JAK inhibitors, salts of the compounds and therapeutic use thereof | |
| BRPI0622030A2 (en) | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | |
| CN101155807A (en) | Compounds having tie2 (tek) inhibitory activity | |
| CN100439365C (en) | Compounds and compositions as protein kinase inhibitors | |
| TW201904942A (en) | Substituted 5-cyanoguanidine compound and its use | |
| CN101679412A (en) | Purine ketone and 1H-imidazopyridine ketone as the PKC-theta inhibitors | |
| TW201103944A (en) | 2-carboxamide cycloamino ureas | |
| WO2015058661A1 (en) | Bcr-abl kinase inhibitor and application thereof | |
| CN101142215A (en) | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | |
| WO2023279938A1 (en) | 2,6,8-polysubstituted imidazo[1,2-a]pyrazine, and synthesis method therefor and use thereof | |
| CN104662022A (en) | Means and method for treating solid tumours | |
| Yuan et al. | Discovery of potent and selective receptor-interacting serine/threonine protein kinase 2 (RIPK2) inhibitors for the treatment of inflammatory bowel diseases (IBDs) | |
| TW200938546A (en) | Triazolotriazines and triazolopyrazines and their use | |
| CN107151233A (en) | Pyridine derivatives containing hydrazone and application thereof | |
| CN105153150B (en) | One class pyridine salt JAK inhibitor, preparation method and its usage | |
| TWI546304B (en) | Protein tyrosine kinase inhibitors and their use | |
| CN105111204B (en) | Pyridine salt tyrosine kinase inhibitor, preparation method and its usage | |
| CN105085519B (en) | The pyridine salt JAK inhibitor of one class nitro replacement, preparation method and its usage | |
| CN105503860B (en) | The pyridine salt JAK inhibitor of one class itrile group replacement, preparation method and its usage | |
| CN105085518B (en) | One class amido substituted pyridine salt JAK inhibitor, preparation method and its usage | |
| CN105061423B (en) | Pyridine salt JAK inhibitor containing halogeno-benzene structure, preparation method and its usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |